Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 8/20 | 0.51 |
| ▸ | MAOB | P27338 | 8/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19450575 | 0.85 | HTR1A (0.38) | MAOAMAOBTDP1HTR1ADRD2 | |
| SCHEMBL29467074 | 0.84 | MAOA (0.57) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL2536091 | 0.84 | MAOA (0.57) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL19451115 | 0.82 | FURIN (0.39) | MAOAMAOBNPC1RAB9AHTR1A | |
| SCHEMBL2534095 | 0.81 | MAOA (0.54) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL3036856 | 0.81 | SMN1; SMN2 (0.47) | RAB9AALDH1A1L3MBTL1DRD1HTT | |
| SCHEMBL2203216 | 0.80 | MAOA (0.60) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL21910885 | 0.80 | MAOA (0.53) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL2533891 | 0.78 | MAOA (0.57) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL17103203 | 0.78 | MAOA (0.57) | MAOAMAOBNPC1RAB9ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382205-B2 | Processes for the manufacture of a pharmaceutically active agent | H. LUNDBECK A/S (DK) | 2016-07-05 | — | — | US | claimed |
| EP-2516394-B1 | PROCESSES FOR THE MANUFACTURE OF A PHARMACEUTICALLY ACTIVE AGENT | LUNDBECK & CO AS H (DK) | 2016-03-16 | — | — | EP | claimed |
| US-20150080584-A1 | PROCESSES FOR THE MANUFACTURE OF A PHARMACEUTICALLY ACTIVE AGENT | H. LUNDBECK A/S (DK) | 2015-03-19 | — | — | US | claimed |
| US-20250034101-A1 | COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2025-01-30 | — | — | US | disclosed |
| US-12145914-B2 | Compound having oxadiazole and pharmaceutical composition containing the same | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2024-11-19 | — | — | US | disclosed |
| US-20230150955-A1 | COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-05-18 | — | — | US | disclosed |
| US-20230150955-A1 | COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-05-18 | — | — | US | disclosed |
| US-20230150955-A1 | COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-05-18 | — | — | US | disclosed |
| US-11603358-B2 | Compound having oxadiazole and pharmaceutical composition containing the same | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-03-14 | — | — | US | disclosed |
| US-20220024886-A1 | COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | SK BIOPHARMACEUTICALS CO., LTD. | 2022-01-27 | — | — | US | disclosed |
| US-20220024886-A1 | COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | SK BIOPHARMACEUTICALS CO., LTD. | 2022-01-27 | — | — | US | disclosed |
| US-20090306110-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | CHEN ZHAOGEN | 2009-12-10 | — | — | US | disclosed |
| EP-1859798-A1 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2007-11-28 | — | — | EP | disclosed |
| EP-1379239-B1 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | LILLY CO ELI (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20070099909-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | CHEN ZHAOGEN | 2007-05-03 | — | — | US | disclosed |
| US-7157488-B2 | N-(2-Arylethyl) benzylamines as antagonists of the 5-HT6 receptor | ELI LILLY AND COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-20060009511-A9 | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor | CHEN ZHAOGEN | 2006-01-12 | — | — | US | disclosed |
| CN-1610547-A | N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor | LILLY CO ELI (US) | 2005-04-27 | — | — | CN | disclosed |
| EP-1379239-A2 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002078693-A2 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150955-A1 | COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | OTC, OXA1L, ATP6V1B2 | MAOA 690/4885MAOB 407/4885NPC1 1158/4885 |
| US-20220024886-A1 | COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | OTC, OXA1L, ATP6V1B2 | MAOA 690/4885MAOB 407/4885NPC1 1158/4885 |
| US-20150080584-A1 | PROCESSES FOR THE MANUFACTURE OF A PHARMACEUTICALLY ACTIVE AGENT | CEL, DCPS, HPSE | MAOA 292/4885MAOB 496/4885NPC1 849/4885 |
| US-20060009511-A9 | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor | HTR6, HTR2C, HTR1B | MAOA 75/4885MAOB 93/4885NPC1 2564/4885 |
| US-20250034101-A1 | COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | OTC, OXA1L, ATP6V1B2 | MAOA 690/4885MAOB 407/4885NPC1 1158/4885 |
| US-20090306110-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | HTR6, HTR2C, HTR1B | MAOA 75/4885MAOB 93/4885NPC1 2564/4885 |
| US-11603358-B2 | Compound having oxadiazole and pharmaceutical composition containing the same | OTC, OXA1L, ATP6V1B2 | MAOA 690/4885MAOB 407/4885NPC1 1158/4885 |
| US-20070099909-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | HTR6, HTR2C, HTR1B | MAOA 75/4885MAOB 93/4885NPC1 2564/4885 |
| US-12145914-B2 | Compound having oxadiazole and pharmaceutical composition containing the same | OTC, OXA1L, ATP6V1B2 | MAOA 690/4885MAOB 407/4885NPC1 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.